Semaglutide Month 3 Results: Average Weight Loss & What to Expect
Semaglutide month 3 results: average weight loss of 10-15 lbs (4-7%), typical dose of 1.0 mg, side effects, and how results compare to STEP trial data at this stage.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. This article is part of our semaglutide monthly results series, providing evidence-based expectations for each month of treatment.
Quick links: Semaglutide treatment, complete results overview, and dosage guide.
More on Semaglutide Timeline
Semaglutide Month 2 Results
What to expect from semaglutide treatment at month 2.
Semaglutide Month 4 Results
What to expect from semaglutide treatment at month 4.
Semaglutide Week 13
Detailed week 13 guide for semaglutide patients.
Semaglutide Weight Loss Results
Comprehensive overview of semaglutide weight loss outcomes.
Semaglutide Month 3: Overview
By month 3, patients have typically escalated to 1.0 mg weekly and are reaching the lower end of the therapeutic dose range. Weight loss becomes clearly noticeable to both the patient and those around them. Cumulative loss of 10 to 15 pounds is common, and many patients report that their relationship with food has fundamentally shifted. Clothing fits differently, and early improvements in energy levels and metabolic markers begin to appear.
Patients using semaglutide at month 3 are typically on a dose of 1.0 mg, which corresponds to the therapeutic dose range phase of the treatment protocol. The weight loss figures discussed in this article are based on data from the STEP clinical trial program and corroborated by real-world patient outcomes reported across telehealth platforms including Trimi.
Average Weight Loss at Month 3
At month 3 of semaglutide treatment, most patients have achieved cumulative weight loss of 10 to 15 pounds, which represents approximately 4 to 7 percent of their starting body weight. These figures are consistent with the trajectory established in the STEP 1 clinical trial, where participants on semaglutide 2.4 mg achieved an average weight loss of 14.9 percent over 68 weeks.
Month 3 Weight Loss Summary
Typical cumulative weight loss: 10-15 lbs (4-7% of starting weight). Current dose: 1.0 mg (therapeutic dose range). Approximately week 13 of treatment. Individual results vary based on adherence, metabolism, diet, and exercise.
It is important to recognize that weight loss on semaglutide is not linear. Patients typically see the most rapid weight loss during months 3 through 7, with the rate gradually slowing thereafter as the body approaches a new equilibrium weight. This trajectory is well documented in clinical literature and should not be interpreted as treatment failure. For detailed information on how dosing affects weight loss pace, see our semaglutide dosage guide.
Dose Level and Titration at Month 3
By month 3, most patients have escalated to 1.0 mg weekly as part of the standard titration schedule. This dose represents therapeutic dose range and is associated with increasing appetite suppression and accelerating weight loss. The titration schedule is designed to balance efficacy with tolerability, ensuring that patients can maintain the dose long-term without significant side effects.
Your healthcare provider at Trimi will monitor your progress and tolerance at each dose level, making adjustments as needed to optimize your treatment. The standard titration schedule is a guideline, and individual patients may progress faster or slower based on their response and tolerance profile.
What Patients Typically Experience at Month 3
By month 3, patients have typically settled into a comfortable routine with their semaglutide treatment. The dramatic appetite changes that characterized early treatment have become the new normal, and patients report that their eating patterns have naturally shifted toward smaller portions, healthier food choices, and less frequent snacking. Many patients at this stage notice that their physical appearance has changed noticeably, with clothing fitting differently and comments from friends, family, and colleagues about their transformation.
Appetite suppression becoming noticeable, particularly around meals and typical snacking times
Possible gastrointestinal adjustment including mild nausea, especially around dose increases
Early improvements in energy levels and overall well-being
Beginning to establish new eating patterns and relationship with food
Visible physical changes becoming apparent to yourself and others
Side Effects at Month 3
Side effects during month 3 are most commonly gastrointestinal in nature. Nausea is the most frequently reported effect, occurring in approximately 40 to 45 percent of patients during the dose escalation phase. Constipation, diarrhea, and abdominal discomfort are also common but typically mild. These effects usually peak around dose increases and diminish as the body adjusts to each new dose level. Most patients find that side effects are manageable and do not require treatment discontinuation.
For comprehensive information about managing side effects at any stage of treatment, see our detailed guide to semaglutide side effects. If you experience severe, persistent, or concerning side effects at any point, contact your healthcare provider promptly.
Comparing Month 3 Results to STEP Trial Data
The STEP clinical trial program provides the benchmark against which semaglutide weight loss results are typically measured. In STEP 1, participants on semaglutide 2.4 mg achieved a mean weight loss of 14.9 percent over 68 weeks, with approximately one-third of participants losing 20 percent or more of their body weight. STEP 3, which combined semaglutide with intensive behavioral therapy, showed even greater average weight loss of 16 percent.
At month 3, a cumulative weight loss of 4 to 7 percent places most patients on track with the STEP trial trajectory. Patients who are in the lower end of this range should not be discouraged, as weight loss often accelerates as the dose increases and the treatment duration extends. It is also important to note that clinical trial participants received structured dietary and exercise counseling, which may contribute to slightly different outcomes than real-world settings.
For a broader perspective on expected outcomes, visit our comprehensive semaglutide weight loss results overview, which aggregates data from multiple clinical trials and real-world studies.
Health Improvements Beyond the Scale
Even at month 3, with relatively modest weight loss, patients may already be seeing improvements in metabolic health markers. Studies show that even a 3 to 5 percent reduction in body weight can produce meaningful improvements in blood pressure, fasting glucose, and triglyceride levels. These early metabolic benefits are encouraging signs that the treatment is producing real physiological changes beyond what the scale shows.
GLP-1 medications like semaglutide and tirzepatide are increasingly recognized for their benefits beyond weight loss. To understand the full scope of these medications, see our complete GLP-1 guide.
Tips for Maximizing Results at Month 3
Prioritize protein at every meal: aim for 25 to 30 grams per meal to support muscle preservation and satiety
Stay consistent with your injection schedule: same day each week, at a time that is easy to remember
Track progress beyond the scale: measure waist circumference, take progress photos, and note how clothing fits
Maintain regular physical activity: combine cardiovascular exercise with resistance training for optimal body composition
Stay hydrated: dehydration can exacerbate side effects and may be mistaken for hunger
Communicate with your provider: report any concerns, side effects, or questions promptly through your Trimi dashboard
Trimi's medical team provides personalized support at every stage of treatment, helping you optimize your results with evidence-based guidance. With transparent pricing and no long-term contracts, you can focus on your health without financial uncertainty.
Looking Ahead: What Comes After Month 3
As you move beyond month 3, you can expect continued progress on your semaglutide treatment. Your dose will continue to increase according to the titration schedule, and weight loss typically accelerates as you reach higher doses. For a preview of what to expect in the coming month, see our month 4 results guide.
Frequently Asked Questions
How much weight will I lose after 3 months on semaglutide?
After 3 months on semaglutide, most patients lose approximately 10 to 15 pounds, representing roughly 4 to 7 percent of their starting body weight. Individual results vary significantly based on starting weight, metabolic factors, dietary adherence, physical activity, and medication compliance. The STEP clinical trials showed average weight loss of 15 to 17 percent over approximately 16 months, and month 3 results should be evaluated in the context of that overall timeline.
What dose of semaglutide should I be on at month 3?
At month 3, most patients are on 1.0 mg of semaglutide (therapeutic dose range). The standard titration schedule starts at 0.25 mg for weeks 1 through 4, increases to 0.5 mg for weeks 5 through 8, then to 1.0 mg for weeks 9 through 12, followed by 1.7 mg for weeks 13 through 16, and reaches the maximum dose of 2.4 mg from week 17 onward. However, your provider may adjust this schedule based on your tolerance and response. Never change your dose without medical guidance.
Is 10 to 15 pounds of weight loss at month 3 a good result?
A weight loss of 10 to 15 pounds at month 3 is consistent with the clinical trial data for semaglutide and represents a clinically meaningful reduction. Even a 5 percent reduction in body weight has been shown to produce significant improvements in blood pressure, blood sugar, cholesterol levels, and overall cardiovascular risk. Weight loss is not linear, and comparing yourself to averages should be done with the understanding that individual trajectories vary widely. Your healthcare provider can help you assess whether your progress is on track for your specific situation.
What side effects are typical at month 3 of semaglutide?
At month 3, the most common side effects include nausea, which affects approximately 40 to 45 percent of patients during dose escalation, along with constipation, diarrhea, and reduced appetite. These gastrointestinal effects are typically most pronounced during the first few months and around dose increases. Most patients find that side effects are manageable and tend to improve as the body adjusts to each new dose level.
How do month 3 semaglutide results compare to the STEP trials?
The STEP 1 clinical trial, which is the primary reference for semaglutide weight loss efficacy, showed that patients on semaglutide 2.4 mg lost an average of 14.9 percent of their body weight over 68 weeks (approximately 16 months). At month 3, your cumulative weight loss of 4 to 7 percent aligns with the trajectory observed in these trials. It is important to note that trial participants received structured dietary counseling and lifestyle support, so real-world results may vary depending on the level of support provided by your treatment platform.
Should I continue semaglutide after month 3?
At month 3, you are still in the active weight loss phase of treatment and have not yet reached the maximum therapeutic potential of semaglutide. Most patients benefit from continuing treatment through at least 12 to 16 months to achieve their full weight loss potential. Stopping at month 3 would likely result in weight regain as the medication's effects on appetite and metabolism would diminish. Always discuss treatment duration decisions with your healthcare provider.
What lifestyle changes should I pair with semaglutide at month 3?
At month 3, the lifestyle habits that complement semaglutide treatment include maintaining adequate protein intake of 0.8 to 1 gram per pound of lean body mass to preserve muscle, engaging in both cardiovascular exercise and resistance training at least 3 to 4 times per week, staying well hydrated with at least 64 ounces of water daily, prioritizing 7 to 9 hours of quality sleep, and managing stress through healthy coping strategies. These habits enhance the medication's effectiveness and build the foundation for long-term weight maintenance regardless of whether you continue on semaglutide indefinitely.
Sources & References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM. 2021;384:989-1002.
- Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 2). Lancet. 2021;397:971-984.
- Wadden TA, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy (STEP 3). JAMA. 2021;325:1403-1413.
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325:1414-1425.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity (SELECT trial). NEJM. 2023;389:2221-2232.
- Wegovy (semaglutide) prescribing information. FDA.
- NIDDK: Prescription medications to treat overweight and obesity.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment program. Individual results vary and the information presented here reflects averages from clinical trials and patient reports.